抗血管生成治疗在糖尿病肾病中的应用：一把双刃剑（综述）。
Antiangiogenic therapy in diabetic nephropathy: A double‑edged sword (Review).
机构信息
Department of Nephrology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213000, P.R. China.
Department of Integrated Traditional Chinese Medicine, Peking University First Hospital, Beijing 100034, P.R. China.
出版信息
Mol Med Rep. 2021 Apr;23(4). doi: 10.3892/mmr.2021.11899. Epub 2021 Feb 8.
Abstract
Diabetes and the associated complications are becoming a serious global threat and an increasing burden to human health and the healthcare systems. Diabetic nephropathy (DN) is the primary cause of end‑stage kidney disease. Abnormal angiogenesis is well established to be implicated in the morphology and pathophysiology of DN. Factors that promote or inhibit angiogenesis serve an important role in DN. In the present review, the current issues associated with the vascular disease in DN are highlighted, and the challenges in the development of treatments are discussed.
摘要
糖尿病及其相关并发症正成为严重的全球威胁，给人类健康和医疗体系带来越来越大的负担。糖尿病肾病（DN）是导致终末期肾病的主要原因。已有充分证据表明，异常血管生成与 DN 的形态和病理生理学有关。促进或抑制血管生成的因素在 DN 中起着重要作用。本综述重点阐述了与 DN 血管疾病相关的当前问题，并讨论了治疗方法开发所面临的挑战。
相似文献
1
Antiangiogenic therapy in diabetic nephropathy: A double‑edged sword (Review).
Mol Med Rep. 2021 Apr;23(4). doi: 10.3892/mmr.2021.11899. Epub 2021 Feb 8.
2
Understanding molecular upsets in diabetic nephropathy to identify novel targets and treatment opportunities.
Drug Discov Today. 2020 May;25(5):862-878. doi: 10.1016/j.drudis.2020.01.008. Epub 2020 Jan 22.
3
Tetramethylpyrazine alleviates diabetic nephropathy through the activation of Akt signalling pathway in rats.
Eur J Pharmacol. 2019 Dec 15;865:172763. doi: 10.1016/j.ejphar.2019.172763. Epub 2019 Nov 1.
4
Effects of renin-angiotensin system blockers on renal and cardiovascular outcomes in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials.
J Endocrinol Invest. 2020 Jul;43(7):959-972. doi: 10.1007/s40618-020-01179-8. Epub 2020 Jan 14.
5
Twenty years after ACEIs and ARBs: emerging treatment strategies for diabetic nephropathy.
Am J Physiol Renal Physiol. 2015 Nov 15;309(10):F807-20. doi: 10.1152/ajprenal.00266.2015. Epub 2015 Sep 2.
6
Phosphodiesterase-5 inhibition preserves renal hemodynamics and function in mice with diabetic kidney disease by modulating miR-22 and BMP7.
Sci Rep. 2017 Mar 15;7:44584. doi: 10.1038/srep44584.
7
Traditional Chinese medicine use is associated with lower end-stage renal disease and mortality rates among patients with diabetic nephropathy: a population-based cohort study.
BMC Complement Altern Med. 2019 Apr 3;19(1):81. doi: 10.1186/s12906-019-2491-y.
8
Improvements in the Management of Diabetic Nephropathy.
Rev Diabet Stud. 2015 Spring-Summer;12(1-2):119-33. doi: 10.1900/RDS.2015.12.119. Epub 2015 Aug 10.
9
The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential.
Biochem Biophys Res Commun. 2009 Jul 10;384(4):471-5. doi: 10.1016/j.bbrc.2009.04.136. Epub 2009 May 5.
10
Potential Renoprotective Agents through Inhibiting CTGF/CCN2 in Diabetic Nephropathy.
J Diabetes Res. 2015;2015:962383. doi: 10.1155/2015/962383. Epub 2015 Sep 2.
引用本文的文献
1
Glomerular ultrastructural change and vascular endothelial growth factor-A expression in diabetic cats.
J Small Anim Pract. 2025 Sep;66(9):600-608. doi: 10.1111/jsap.13884. Epub 2025 Jun 4.
2
Still finding ways to augment the existing management of acute and chronic kidney diseases with targeted gene and cell therapies: Opportunities and hurdles.
Front Med (Lausanne). 2023 Mar 7;10:1143028. doi: 10.3389/fmed.2023.1143028. eCollection 2023.
3
Antioxidant and Anti-inflammatory Properties of Resveratrol in Diabetic Nephropathy: A Systematic Review and Meta-analysis of Animal Studies.
Front Pharmacol. 2022 Mar 9;13:841818. doi: 10.3389/fphar.2022.841818. eCollection 2022.
4
Role of Endothelial Glucocorticoid Receptor in the Pathogenesis of Kidney Diseases.
Int J Mol Sci. 2021 Dec 10;22(24):13295. doi: 10.3390/ijms222413295.
本文引用的文献
1
FGF/FGFR signaling in health and disease.
Signal Transduct Target Ther. 2020 Sep 2;5(1):181. doi: 10.1038/s41392-020-00222-7.
2
Fibroblast Growth Factor 23 and Adverse Clinical Outcomes in Type 2 Diabetes: a Bitter-Sweet Symphony.
Curr Diab Rep. 2020 Aug 28;20(10):50. doi: 10.1007/s11892-020-01335-7.
3
Transforming Growth Factor-Beta1 in Diabetic Kidney Disease.
Front Cell Dev Biol. 2020 Mar 24;8:187. doi: 10.3389/fcell.2020.00187. eCollection 2020.
4
Intravitreal bevacizumab-induced exacerbation of proteinuria in diabetic nephropathy, and amelioration by switching to ranibizumab.
SAGE Open Med Case Rep. 2020 Feb 16;8:2050313X20907033. doi: 10.1177/2050313X20907033. eCollection 2020.
5
Intravitreal Injection of Anti-VEGF Antibody Induces Glomerular Endothelial Cells Injury.
Case Rep Nephrol. 2019 Dec 21;2019:2919080. doi: 10.1155/2019/2919080. eCollection 2019.
6
Netrin-1 works with UNC5B to regulate angiogenesis in diabetic kidney disease.
Front Med. 2020 Jun;14(3):293-304. doi: 10.1007/s11684-019-0715-7. Epub 2019 Dec 28.
7
Fibroblast Growth Factor 21 Attenuates Diabetes-Induced Renal Fibrosis by Negatively Regulating TGF-β-p53-Smad2/3-Mediated Epithelial-to-Mesenchymal Transition via Activation of AKT.
Diabetes Metab J. 2020 Feb;44(1):158-172. doi: 10.4093/dmj.2018.0235. Epub 2019 Oct 28.
8
Circ_0080425 inhibits cell proliferation and fibrosis in diabetic nephropathy via sponging miR-24-3p and targeting fibroblast growth factor 11.
J Cell Physiol. 2020 May;235(5):4520-4529. doi: 10.1002/jcp.29329. Epub 2019 Nov 3.
9
The single-cell transcriptomic landscape of early human diabetic nephropathy.
Proc Natl Acad Sci U S A. 2019 Sep 24;116(39):19619-19625. doi: 10.1073/pnas.1908706116. Epub 2019 Sep 10.
10
Safety of anti-VEGF treatments in a diabetic rat model and retinal cell culture.
Clin Ophthalmol. 2019 Jul 1;13:1097-1114. doi: 10.2147/OPTH.S199771. eCollection 2019.
Zotero 插件